WO2019114258A1 - 一种巴瑞替尼的制备方法 - Google Patents
一种巴瑞替尼的制备方法 Download PDFInfo
- Publication number
- WO2019114258A1 WO2019114258A1 PCT/CN2018/094160 CN2018094160W WO2019114258A1 WO 2019114258 A1 WO2019114258 A1 WO 2019114258A1 CN 2018094160 W CN2018094160 W CN 2018094160W WO 2019114258 A1 WO2019114258 A1 WO 2019114258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- reaction
- mol
- baritinib
- added
- Prior art date
Links
- MOPJSMIEGALASX-UHFFFAOYSA-N BrCC1(CBr)OCCO1 Chemical compound BrCC1(CBr)OCCO1 MOPJSMIEGALASX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention belongs to the technical field of pharmaceutical preparation, and in particular relates to a preparation method of selective JAK1 and JAK2 inhibitor barritinib.
- Baricitinib chemical name 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazole-1 -Alkyl-3-azetidine acetonitrile, a selective oral JAK1/JAK2 inhibitor developed by Eli Lilly and Inc. in collaboration with Incyte Pharmaceuticals, which inhibits various inflammatory cells such as IL-6 and IL-23. Intracellular signaling of the factor, this product can be used for the treatment of moderate to severe rheumatoid arthritis.
- the method uses 4-pyrazoleboronic acid pinacol ester and 3-(cyanomethylene)azetidin-1-carboxylic acid tert-butyl ester as starting materials to obtain compound 9, compound by Michael addition reaction.
- the intermediate 11 is obtained by catalytic coupling reaction with the starting material compound 10; the intermediate 11 is obtained by removing two molecules of tert-butyl formate to obtain the intermediate 12; the intermediate 12 and the ethylsulfonyl chloride are sulfonated in an organic solvent.
- the amidation reaction produces the final product, barritinib (Compound 1).
- starting compound 7 and compound 8 are difficult to purchase, and the last step in the invention is because of the two amino groups having better activity, and it is highly prone to disubstituted or ethylsulfonyl chloride and pyrrole ring when reacted with ethylsulfonyl chloride.
- the amino group reacts, so as far as this step is concerned, there are many by-products.
- precious metal palladium is used in the reaction, and the total cost is relatively high, which is not suitable for industrial production.
- the route is based on 4-chloropyrrolopyrimidine, first protected with 2-(trimethylsilyl)ethoxymethyl chloride (SEMCl) to give SEM protected 4-chloropyrrolopyrimidine, followed by boronate compound 17
- SEMCl 2-(trimethylsilyl)ethoxymethyl chloride
- the compound was prepared by Suzuki coupling reaction, and the compound 18 was prepared by deprotecting 1-ethoxyethyl chloride with aqueous hydrochloric acid to obtain pyrazole compound 19.
- the obtained compound 6 and compound 19 were prepared by Michael addition reaction under DBU catalysis.
- Compound 20 Compound 20 was finally deprotected in two steps by LIBF 4 and NH 4 OH to give the final product, Baritinib.
- the reaction route is too long, the total yield is low, the operation is cumbersome, and palladium is used twice in the reaction, and the finished product is relatively high, which is not suitable for industrial production.
- the present invention is directed to the above-mentioned deficiencies, and provides a preparation method of baritinib, which is easy to obtain raw materials, easy to handle, and has a lower preparation method.
- the invention adopts 4-chloropyrrolopyrimidine as a starting material, first carries out amino protection, directly or after distilling off the solvent, and then replaces and closes the ring with hydrazine hydrate and acrolein to obtain the middle 4.
- the starting material 1,3-dibromoacetone and ethylene glycol are condensed to obtain intermediate 5, intermediate 5 is condensed with ethylsulfonamide to obtain intermediate 6, and intermediate 6 and diethyl cyanomethyl phosphate are eliminated under strong alkali.
- the intermediate 7 is obtained, and the intermediate 4 and the intermediate 7 are subjected to an addition reaction in the action of the catalyst, and the target product is deprotected much, and the total yield is 40 to 55%.
- the disadvantages of the current conventional preparation method that the route is too long, the operation is cumbersome, or the raw materials are not easy to obtain, or the precious metal palladium is used for the Michael addition is avoided.
- the present invention provides a preparation method of baritinib.
- a preparation method of baritinib comprises the following steps:
- R is an amino-protecting compound such as an alkoxycarbonyl group, including di-tert-butyl dicarbonate, ((Boc) 2 O), fluorenylmethoxycarbonyl chloride (Fmoc-Cl), benzylcarbonyl (Cbz-Cl); acyl group, Including p-toluenesulfonyl chloride (TS-Cl), trifluoroacetyl chloride (Tfa-Cl); alkyls, including chlorotriphenylmethane (Trt-Cl), p-methoxybenzyl bromide (or chlorine) (PMB- Br, or PMB-Cl)
- an alkoxycarbonyl group including di-tert-butyl dicarbonate, ((Boc) 2 O), fluorenylmethoxycarbonyl chloride (Fmoc-Cl), benzylcarbonyl (Cbz-Cl); acyl group, Including
- R' is a protective group corresponding to R, such as tert-butoxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fomc), benzylcarbonyl (Cbz), p-methylsulfonyl (TS), trifluoroacetyl chloride (Tfa), Chlorotriphenylmethane (Trt), p-methoxybenzyl (PMB)
- the organic solvent described in the step (1) is one of tetrahydrofuran, toluene, xylene, or o-dichlorobenzene;
- the molar ratio of 4-chloropyrrolopyrimidine, hydrazine hydrate, and acrolein described in the step (1) is 1:1:1 to 1:4:4.
- the strong acid catalyst described in step (2) is one of p-toluenesulfonic acid, sulfuric acid.
- the base described in the step (3) is one of potassium carbonate, sodium carbonate, and cesium carbonate, preferably cesium carbonate; the reaction temperature is 50 to 80 ° C.
- the base described in the step (3) is cesium carbonate, the reaction temperature is 65 ° C;
- the strong base described in the step (4) is one of sodium hydride, potassium hydride, sodium methoxide, and sodium ethoxide; and the reaction temperature is 10 to 40 ° C.
- the catalyst described in the step (5) is one of DBU, TBAB, and TEBA; and the reaction temperature is 40 to 70 °C.
- the present invention avoids the problem of high cost caused by the use of metal palladium in the Suzuki coupling reaction in the conventional synthesis method of baritinib;
- the invention uses the amino protecting group ingeniously to avoid the participation of the amino group in the pyrrole ring, reduces the possibility of by-product generation, and improves the quality and total yield of the intermediate and the finished product;
- the invention adopts the starting materials which are cheap and easy to obtain, and the reaction route is much shorter than the conventional route, the reaction conditions are mild, and it is suitable for industrial production.
- the organic layer was placed in a 2 L clean reaction flask, and 30.4 g of concentrated hydrochloric acid was added dropwise with stirring at room temperature. After the dropwise addition, the mixture was stirred for 1 hour, and the organic layer was washed with 500 g of water, dried, filtered, and the filtrate was concentrated to half, 300 g of n-heptane was added, the system was cooled to 0-10 ° C, and the filter cake was dried for 2 h, and the filter cake was dried to a compound of about 22.6. g, yield: 92.4%, HPLC ⁇ 98.0%.
- the aqueous layer was extracted with 100 g of ethyl acetate. Concentrated hydrochloric acid, after stirring for 30 min, filtered, adding 300 g of fresh ethyl acetate to the cake, adjusting the pH to neutral with 10% potassium carbonate solution under stirring, layering, drying the organic layer, filtering, and drying the cake to obtain a white solid. 16.6 g, HPLC ⁇ 99.0% (see Figure 2 HPLC: 99.82%), yield: 89.3%.
- the hydrogen spectrum of the target product 1 is shown in Figure 1.
- the organic layer was placed in a 2 L clean reaction flask, and 30.4 g of concentrated hydrochloric acid was added dropwise with stirring at room temperature. After completion of the dropwise addition, the mixture was stirred for 1 h, and the organic layer was washed with 500 g of water, dried, filtered, and the filtrate was concentrated to half, 300 g of n-heptane was added, and the system was cooled to 0-10 ° C. After 2 h of thermal padding, the filter cake was filtered and dried to a compound of about 22.8. g, yield: 93.1%, HPLC ⁇ 98.0%.
- the organic layer was placed in a 2 L clean reaction flask, and 30.4 g of concentrated hydrochloric acid was added dropwise with stirring at room temperature. After the dropwise addition, the mixture was stirred for 1 hour, and the organic layer was washed with 500 g of water, dried, filtered, and the filtrate was concentrated to half, 300 g of n-heptane was added, the system was cooled to 0-10 ° C, and the filter cake was dried for 2 h, and then filtered to dry to 6 to about 23.0. g, yield: 94.1%, HPLC ⁇ 98.0%.
- the organic layer was placed in a 2 L clean reaction flask, and 30.4 g of concentrated hydrochloric acid was added dropwise with stirring at room temperature. After the dropwise addition, the mixture was stirred for 1 hour, and the organic layer was washed with 500 g of water, dried, filtered, and the filtrate was concentrated to half, 300 g of n-heptane was added, the system was cooled to 0-10 ° C, and the filter cake was dried for 2 h, and the filter cake was dried to the compound 6 about 22.1. g, yield: 90.2%, HPLC ⁇ 98.0%.
- the organic layer was combined and the organic layer was washed with 500 g of water.
- the organic layer was placed in a 2 L clean reaction flask, and 30.4 g of concentrated hydrochloric acid was added dropwise with stirring at room temperature. After the dropwise addition, the mixture was stirred for 1 hour, and the organic layer was washed with 500 g of water, dried, filtered, and the filtrate was concentrated to half, 300 g of n-heptane was added, the system was cooled to 0-10 ° C, and the filter cake was dried for 2 hours, and the filter cake was dried to a compound of about 24.5. g, yield: 93.4%, HPLC ⁇ 98.0%.
Abstract
Description
Claims (9)
- 一种巴瑞替尼的制备方法,其特征在于:反应步骤为:(1)以4-氯吡咯并嘧啶为原料,与氨基保护基R进行氨基保护后得到中间态化合物3,后在氧气下和有机溶剂中与水合肼及丙烯醛经“一锅法”取代、环合、重结晶得到化合物4;其中,所述的氨基保护化合物R为二碳酸二叔丁酯((Boc) 2O),芴甲氧羰酰氯(Fmoc-Cl),苄基羰基(Cbz-Cl);对甲苯磺酰氯(TS-Cl),三氟乙酰氯(Tfa-Cl);氯代三苯甲烷(Trt-Cl),对甲氧基苄溴(PMB-Br)或对甲氧基苄溴氯(PMB-Cl);R’为R对应的保护基团,为叔丁氧羰基(Boc),笏甲氧羰基(Fomc),苄基羰基(Cbz),对甲磺酰基(TS),三氟乙酰氯(Tfa),氯代三苯甲烷(Trt),对甲氧基苄基(PMB);(2)以1,3-二溴丙酮和乙二醇为原料,在强酸催化下缩合得到羰基保护物化合物5;(3)将步骤(2)所得化合物5与乙基磺酰胺在碱作用下,加热发生环合,得到化合物6;(4)原料氰甲基磷酸二乙酯与步骤(3)中化合物6在强碱下消去得到化合物7;(5)将步骤(1)所得化合物4与步骤(4)所得化合物7在有机溶剂中于催化剂作用下发生加成、脱氨基保护基得到巴瑞替尼。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(1)中所述的有机溶剂为四氢呋喃,甲苯,二甲苯,邻二氯苯中的一种。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(1)中所述的4-氯吡咯并嘧啶,水合肼,丙烯醛的摩尔比为1∶1∶1-1∶4∶4。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(1)中所述的重结晶溶剂为甲基叔丁基醚/正己烷、甲基叔丁醚/正庚烷、乙醚/正己烷或乙醚/正庚烷。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(2)中所述的强酸催化剂为对甲苯磺酸,硫酸中的一种。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(3)中所述的碱为碳酸钾,碳酸钠,碳酸铯中的一种;反应温度为50~80℃。
- 根据权利要求6所述的巴瑞替尼的制备方法,其特征在于,步骤(3)中所述的碱为碳酸铯,反应温度为65℃。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(4)中所述的强碱为氢化钠,氢化钾,甲醇钠,乙醇钠中的一种;反应温度为10~40℃。
- 根据权利要求1所述的巴瑞替尼的制备方法,其特征在于,步骤(5)中所述的催化剂为DBU,TBAB,TEBA中的一种;反应温度为40~70℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018366342A AU2018366342A1 (en) | 2017-12-13 | 2018-07-03 | Method for preparing Baricitinib |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711334329.1 | 2017-12-13 | ||
CN201711334329.1A CN108129482A (zh) | 2017-12-13 | 2017-12-13 | 一种巴瑞替尼的制备方法 |
CN201810667443.4A CN108586465B (zh) | 2017-12-13 | 2018-06-25 | 一种巴瑞替尼的制备方法 |
CN201810667443.4 | 2018-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019114258A1 true WO2019114258A1 (zh) | 2019-06-20 |
Family
ID=62389618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/094160 WO2019114258A1 (zh) | 2017-12-13 | 2018-07-03 | 一种巴瑞替尼的制备方法 |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN108129482A (zh) |
AU (2) | AU2018102141A4 (zh) |
WO (1) | WO2019114258A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108129482A (zh) * | 2017-12-13 | 2018-06-08 | 江苏中邦制药有限公司 | 一种巴瑞替尼的制备方法 |
WO2021053690A1 (en) * | 2019-09-17 | 2021-03-25 | Natco Pharma Limited | An improved process for the preparation of baricitinib |
CN111362853A (zh) * | 2020-04-27 | 2020-07-03 | 安徽大学 | 一种3-氧杂氮杂环丁烷-1-羧酸叔丁酯的制备方法 |
CN112898306B (zh) * | 2021-02-02 | 2022-04-08 | 山东四环药业股份有限公司 | 一种巴瑞替尼的制备方法 |
CN115124537A (zh) * | 2022-07-13 | 2022-09-30 | 山东大学 | 一种jak抑制剂巴瑞替尼的制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434292A (en) * | 1980-09-19 | 1984-02-28 | Bayer Aktiengesellschaft | Process for the preparation of pyrazole |
CN103788098A (zh) * | 2008-03-11 | 2014-05-14 | 因塞特公司 | 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物 |
CN105294699A (zh) * | 2015-12-04 | 2016-02-03 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
CN105541891A (zh) * | 2016-02-04 | 2016-05-04 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
WO2016125080A2 (en) * | 2015-02-02 | 2016-08-11 | Sun Pharmaceutical Industries Limited | Process for the preparation of baricitinib and an intermediate thereof |
CN106496195A (zh) * | 2016-10-18 | 2017-03-15 | 杭州科巢生物科技有限公司 | 巴瑞替尼及其中间体的新合成方法 |
CN106946917A (zh) * | 2017-03-20 | 2017-07-14 | 杭州科巢生物科技有限公司 | 一种jak抑制剂巴瑞替尼及其中间体的新合成方法 |
CN107176955A (zh) * | 2017-03-24 | 2017-09-19 | 南京优科制药有限公司 | 一种巴瑞替尼的制备方法 |
CN108129482A (zh) * | 2017-12-13 | 2018-06-08 | 江苏中邦制药有限公司 | 一种巴瑞替尼的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631792B (zh) * | 2007-02-28 | 2013-05-01 | 利奥制药有限公司 | 新的磷酸二酯酶抑制剂 |
WO2016088094A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Process for the preparation of baricitinib and an intermediate thereof |
AR104918A1 (es) * | 2015-06-19 | 2017-08-23 | Lilly Co Eli | Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo |
CN107739328B (zh) * | 2017-11-22 | 2020-03-20 | 海化生命(厦门)科技有限公司 | 用于合成巴瑞替尼的关键中间体1的制备方法 |
-
2017
- 2017-12-13 CN CN201711334329.1A patent/CN108129482A/zh not_active Withdrawn
-
2018
- 2018-06-25 CN CN201810667443.4A patent/CN108586465B/zh active Active
- 2018-07-03 WO PCT/CN2018/094160 patent/WO2019114258A1/zh active Application Filing
- 2018-07-03 AU AU2018102141A patent/AU2018102141A4/en active Active
- 2018-07-03 AU AU2018366342A patent/AU2018366342A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434292A (en) * | 1980-09-19 | 1984-02-28 | Bayer Aktiengesellschaft | Process for the preparation of pyrazole |
CN103788098A (zh) * | 2008-03-11 | 2014-05-14 | 因塞特公司 | 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物 |
WO2016125080A2 (en) * | 2015-02-02 | 2016-08-11 | Sun Pharmaceutical Industries Limited | Process for the preparation of baricitinib and an intermediate thereof |
CN105294699A (zh) * | 2015-12-04 | 2016-02-03 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
CN105541891A (zh) * | 2016-02-04 | 2016-05-04 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
CN106496195A (zh) * | 2016-10-18 | 2017-03-15 | 杭州科巢生物科技有限公司 | 巴瑞替尼及其中间体的新合成方法 |
CN106946917A (zh) * | 2017-03-20 | 2017-07-14 | 杭州科巢生物科技有限公司 | 一种jak抑制剂巴瑞替尼及其中间体的新合成方法 |
CN107176955A (zh) * | 2017-03-24 | 2017-09-19 | 南京优科制药有限公司 | 一种巴瑞替尼的制备方法 |
CN108129482A (zh) * | 2017-12-13 | 2018-06-08 | 江苏中邦制药有限公司 | 一种巴瑞替尼的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2018366342A1 (en) | 2019-07-04 |
CN108586465A (zh) | 2018-09-28 |
CN108586465B (zh) | 2020-06-02 |
AU2018102141A4 (en) | 2019-10-03 |
CN108129482A (zh) | 2018-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019114258A1 (zh) | 一种巴瑞替尼的制备方法 | |
CZ20032534A3 (cs) | N-Fenpropylcyklopentylem substituované glutaramidové deriváty jako NEP inhibitory pro FSAD | |
CN112321602A (zh) | 一种瑞卢戈利药物中间体的制备方法 | |
KR20170131508A (ko) | 레디파스비르 및 이의 유도체의 제조방법 및 레디파스비르를 제조하기 위한 중간체 화합물 | |
WO2019019795A1 (zh) | 一种沙库必曲中间体的制备方法 | |
KR20050099525A (ko) | 피롤로트리아진 키나제 억제제의 제조 방법 | |
JP6454707B2 (ja) | trans−8−クロロ−5−メチル−1−[4−(ピリジン−2−イルオキシ)−シクロヘキシル]−5,6−ジヒドロ−4H−2,3,5,10b−テトラアザ−ベンゾ[e]アズレン及びその結晶形態の合成 | |
US20170369437A1 (en) | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | |
WO1997043265A1 (fr) | Procedes de preparation d'un compose pyrimidine | |
JP2921760B2 (ja) | フタルイミド誘導体及びそれら誘導体を含んでなる医薬 | |
JPS638368A (ja) | 4−ベンジロキシ−3−ピロリン−2−オン−1−イルアセトアミド、その製造方法および使用方法 | |
CN113583003A (zh) | 一种伐地那非类似物及其合成方法和应用 | |
CN112679363A (zh) | 一种制备喷他佐辛中间体的方法 | |
CN107739328B (zh) | 用于合成巴瑞替尼的关键中间体1的制备方法 | |
WO2015188762A1 (zh) | 一种抗血管新生化合物及其中间体的制备方法 | |
KR20210092768A (ko) | 1-((3s,4r)-4-(2,6-디플루오로-4-메톡시페닐)-2-옥소피롤리딘-3-일)-3-페닐우레아의 제조를 위한 합성 방법 | |
JP4790901B2 (ja) | 4−アミノ−5−シアノイミダゾール誘導体及びその中間体の製造方法 | |
CN111560021B (zh) | 一种德高替尼中间体及其制备方法 | |
CN112898306B (zh) | 一种巴瑞替尼的制备方法 | |
CN117285537B (zh) | 一种乌帕替尼的制备方法 | |
JP4699582B2 (ja) | 1h−4(5)−アミノイミダゾール−5(4)−カルボキサミドの製造方法 | |
WO2024092892A1 (zh) | 依度沙班中间体及其制备方法 | |
CN115124473B (zh) | 西咪替丁有关物质b的合成方法 | |
CN111362852B (zh) | 一种药物中间体1-叔丁氧羰基-3-氮杂环丁酮的制备方法 | |
JP2000072744A (ja) | ピロリジニルヒドロキサム酸化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018366342 Country of ref document: AU Date of ref document: 20180703 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018366342 Country of ref document: AU Date of ref document: 20180703 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18888310 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18888310 Country of ref document: EP Kind code of ref document: A1 |